Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Carboplatin (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ELANFIT; GORTEC-ELANFIT
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.
- 14 Jan 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 23 Oct 2018 Planned End Date changed from 1 Dec 2019 to 1 Aug 2021.